Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)

SHE:301075 Revenue

Tibet Duo Rui Pharmaceutical had revenue of 53.35M CNY in the quarter ending September 30, 2026, with 75.36% growth. This brings the company's total for the last twelve months to 166.19M, down -15.56% year-over-year. In the year 2025, Tibet Duo Rui Pharmaceutical had annual revenue of 154.18M, down -35.93%. That makes Tibet Duo Rui Pharmaceutical the 32,514th largest company in the world by revenue and 5,036th in China.

• Revenue (ttm): 166.19M
• Revenue Growth: -15.56%
• P/S Ratio: 23.35
• Revenue / Employee: 360.50K
• Employees: 461
• Market Cap: 3.70B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Preparations 55.36M 35.9%
• Active Pharmaceutical Ingredient (api) 49.74M 32.3%
• Intermediate 38.96M 25.3%
• Others 10.11M 6.6%

Fiscal year ended Dec 31, 2025 See the full SHE:301075 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	154.18M	-86.45M	-35.93%
Dec 31, 2024	240.63M	-93.67M	-28.02%
Dec 31, 2023	334.30M	-66.75M	-16.64%
Jan 1, 2023	401.05M	-128.57M	-24.28%
Jan 1, 2022	529.62M	39.45M	8.05%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error